Mineralys Therapeutics, Inc. MLYS Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsOperatingLossCarryforwards.
The official record: Mineralys Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s deferred tax assets?
- Mineralys Therapeutics, Inc. (MLYS) reported deferred tax assets of $55.1M in Q4 2025.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s deferred tax assets?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s deferred tax assets has grown at a 112.6% compound annual growth rate (CAGR), from $5.74M to $55.1M.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.